Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Activated natural killer cell therapy - ImmunityBio

Next Previous
Drug Profile

Activated natural killer cell therapy - ImmunityBio

Alternative Names: aNK cells - ImmunityBio; CST-101; Neukoplast; NK 92; NK-92 cells; ZRx-101

Latest Information Update: 08 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZelleRx
  • Developer ImmunityBio; Johann Wolfgang Goethe-Universitat Frankfurt am Main; Rush University; University Health Network; University of Pittsburgh Medical Center; ZelleRx
  • Class Anti-infectives; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Merkel cell carcinoma
  • Phase I/II Pancreatic cancer
  • No development reported Acute myeloid leukaemia; Haematological malignancies; Infections; Liver cancer; Malignant melanoma; Renal cancer; Solid tumours
  • Discontinued Graft-versus-host disease; Leukaemia; Multiple myeloma; Sarcoma

Most Recent Events

  • 25 Apr 2025 Pharmacodynamics data from a preclinical study in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 25 Apr 2025 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 28 Jan 2022 No recent reports of development identified for preclinical development in Infections in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top